ArticleCell reports. Medicine2026
Integrative CSF profiling identifies disease-specific immune responses in leptomeningeal disease.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptomeningeal disease (LMD) is a devastating manifestation of advanced cancer, marked by rapid neurological decline and limited treatment options. Immune profiling in central nervous system (CNS) neoplasms, including LMD, is critical for understanding disease biology and guiding therapy. Here, we use single-cell RNA and T cell receptor (TCR) sequencing of cerebrospinal fluid (CSF) from patients with CNS lymphoma (CNSL), brain metastases (BrMs), and glioblastoma (GB), alongside deep TCR sequencing of blood and spatial transcriptomics of brain lesions. We uncover distinct, disease-specific CSF immune landscapes: CNSL-associated LMD shows clonal T cell expansion, while BrMs and GB are enriched in blood-derived and resident-like myeloid cells. Spatial analysis confirms transcriptional similarities between CSF and tumor microenvironments. Longitudinal sampling reveals dynamic immune changes and emerging resistant clones. These findings establish the CSF as an immune-active compartment reflecting disease-specific features and highlight the value of CSF liquid biopsy for immune monitoring and therapeutic stratification in LMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.